Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CCR4 | P51679 | 5/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MYLK | Q15746 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298260 | 0.99 | TP53 (0.47) | TP53CCR4AKT1MYLKMAPK14 | |
| SCHEMBL3293223 | 0.95 | TP53 (0.48) | TP53CCR4AKT1MYLKMAPK14 | |
| SCHEMBL3293263 | 0.94 | TP53 (0.49) | TP53CCR4AKT1MYLKMAPK14 | |
| SCHEMBL3291439 | 0.89 | TP53 (0.48) | TP53CCR4AKT1MYLKMAPK14 | |
| SCHEMBL3293182 | 0.89 | TP53 (0.47) | TP53CCR4AKT1MYLKMAPK14 | |
| SCHEMBL3294975 | 0.89 | TP53 (0.51) | TP53CCR4LMNATHRBHSD11B1 | |
| SCHEMBL3298215 | 0.88 | TP53 (0.51) | TP53CCR4LMNATHRBHSD11B1 | |
| SCHEMBL3295765 | 0.88 | TP53 (0.47) | TP53CCR4AKT1MYLKMAPK14 | |
| SCHEMBL3297199 | 0.88 | TP53 (0.47) | TP53CCR4AKT1MYLKMAPK14 | |
| SCHEMBL3299498 | 0.88 | TP53 (0.47) | TP53CCR4AKT1MYLKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7732442-B2 | Chemokine receptor antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | CCR5, CCR4, CCR1 | TP53 2581/4885CCR4 2/4885AKT1 714/4885 |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | CCR5, CCR4, CCR1 | TP53 2581/4885CCR4 2/4885AKT1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.